Working... Menu

LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02224742
Recruitment Status : Completed
First Posted : August 25, 2014
Last Update Posted : June 25, 2018
Information provided by (Responsible Party):
Nottingham University Hospitals NHS Trust

Brief Summary:

Diabetic foot ulcers are the source of considerable suffering and cost and there are currently no wound care products available that have been demonstrated to improve healing, or that are cost effective. There have however been a small number of studies which have examined the use of platelets or fluid derived from platelets, either from the patient's own blood or from blood bank products. These have suggested some promise, but have suffered from technical difficulties in making a suitable wound care product or the volume of blood required to derive the product. It is thought that the reason why they may work is that growth factors released by the platelets may stimulate the wound to heal.

This study will be a formal, randomised controlled trial to assess a new device for creating a wound care product which is a plug or patch comprising fibrin, white cells and platelets derived from 18 mls of the patients own blood. The application of this fibrin/white cell/platelet patch to the patients wound on a weekly basis will be compared with usual best care in patients with hard to heal Diabetic Foot Ulcers in a secondary care setting in 25 centres in the United Kingdom, Denmark and Sweden.

Condition or disease Intervention/treatment Phase
Diabetic Foot Ulcer Device: LeucoPatch Other: Usual care Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 269 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: LeucoPatch in the Management of Hard-to-heal Diabetic Foot Ulcers
Actual Study Start Date : August 2013
Actual Primary Completion Date : October 2017
Actual Study Completion Date : May 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: LeucoPatch
Usual care supplemented by the application of LeucoPatch centrifugates that comprise autologous fibrin patches containing living white cells and platelets
Device: LeucoPatch
LeucoPatch® is prepared by centrifuging one or more 18mL aliquots of the participant's venous blood in the LeucoPatch device and bench-top centrifuge. The centrifugation yields a tough layer of fibrin, with viable white cells and platelets, and this is applied directly to the wound surface using sterile forceps. The wound is then covered with an inert primary dressing, secondary protective dressing and the ulcerated area protected with appropriate off-loading. The patch is prepared and applied each week for up to 20 weeks or until the wound is judged healed.

Active Comparator: Usual care
Usual care provided in a multidisciplinary foot care clinic, in accordance with international guidelines
Other: Usual care

Usual wound care provided in a multidisciplinary foot care clinic , in accordance with international guidelines.

Components of usual wound care include:

  • Formal assessment of ulcer and surrounding skin
  • Provision of any necessary off-loading
  • Debridement (i) sharp, (ii) other as appropriate (but excluding the use of larvae)
  • Appropriate dressing products
  • Appropriate antibiotic therapy
  • Nutrition and self care
  • Optimal glycaemic control
  • Revascularisation if deemed clinically necessary
  • Continued close observation

Primary Outcome Measures :
  1. Healing [ Time Frame: Within 20 weeks of randomisation ]
    Healing will be defined as complete epithelialisation without discharge that is maintained for 4 weeks and is confirmed by an observer blind to randomisation group.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • People aged 18 years and over who have diabetes complicated by one or more ulcers on a foot or both feet below the level of the malleoli, excluding ulcers confined to the interdigital cleft.
  • Those with more than one eligible ulcer will have one - usually the largest or more clinically significant - selected at screening as the index ulcer.
  • Eligible ulcers will be hard-to-heal, meaning that the cross-sectional area will decrease by less than 50 % during a four week run-in period.
  • The cross-sectional area of the index ulcer will be ≥50 and ≤1000 mm2 at the end of the 4 week run-in period.
  • At randomisation, the index ulcer will be clinically non-infected according to IDSA criteria
  • Either the ankle-brachial index (ABPI) in the affected limb will be between 0.50 and 1.40 or the dorsalis pedis pulse and/or tibialis posterior pulse will be palpable.
  • HbA1c ≤108 mmol/mol at screening
  • Participants will have the capacity to understand study procedures, and will be able to provide written informed consent.

Exclusion Criteria:

  • Haemoglobin concentration <105 g/L or 6.5 mmol/L at screening.
  • Presence of sickle-cell anaemia, haemophilia, thrombocytopenia (<100x109/L) or other clinically significant blood dyscrasia
  • Known potential infectivity of blood products, including known HIV and hepatitis
  • Dialysis or an estimated GFR (based on cystatine C or serum creatinine) <20 ml/min/1.73m2
  • Increase in cross-sectional area of the index ulcer by ≥25% during the 4 week run-in period, or is either smaller than 50 mm2 or larger than 1000 mm2 at the end of that time.
  • Clinical signs of infection of the index ulcer or reason to suspect that infection is present at randomisation.
  • Revascularisation procedure in the affected limb planned, or undertaken within the preceding 4 weeks.
  • Current treatment with cytotoxic drugs or with systemically administered glucocorticoids or other immunosuppressants.
  • Treatment of foot ulcers with growth factors, stem cells or equivalent preparation within the preceding 8 weeks
  • The need for continued use of negative pressure wound therapy
  • Likely inability to comply with the need for weekly visits because of planned activity.
  • Participation in another interventional clinical foot ulcer-healing trial within last the 4 weeks at the time of screening.
  • Prior randomisation in this trial.
  • Judgement by the investigator that the patient does not have the capacity to understand the study procedures or provide written informed consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02224742

Layout table for location information
Steno Diabetes Center
Gentofte, Denmark
Herlev Hospital
Herlev, Denmark
Nordsjællands Hospital
Hillerød, Denmark
Bispebjerg Hospital
Kobenhavn NV, Denmark
Kolding Sygehus
Kolding, Denmark, 6000
Odense University Hospital
Odense, Denmark
Viborg Sårcenter
Viborg, Denmark
Centralsjukhuset Kristianstad
Kristianstad, Sweden
Skåne University Hospital
Lund, Sweden
Karolinska University Hospital
Solna, Sweden
United Kingdom
Royal Cornwall Hospitals NHS Trust
Truro, Cornwall, United Kingdom, TRI 3LJ
South Devon Healthcare NHS Foundation Trust
Torquay, Devon, United Kingdom, TQ2 7AA
The Ipswich Hospital NHS Trust
Ipswich, Suffolk, United Kingdom, IP4 5PD
The Mid Yorkshire Hospitals NHS Trust
Pontefract, West Yorkshire, United Kingdom, WF8 1PL
Barnsley Hospital NHS Foundation Trust
Barnsley, United Kingdom, S75 2EP
Bradford Teaching Hospitals NHS Foundation Trust
Bradford, United Kingdom, BD9 6RJ
Lancashire Teaching Hospitals NHS Foundation Trust
Chorley, United Kingdom, PR7 1PP
Dartford and Gravesham NHS Trust
Dartford, United Kingdom, DA2 8DA
Derby Hospitals NHS Foundation Trust
Derby, United Kingdom, DE22 3NE
The Dudley Group NHS Foundation Trust
Dudley, United Kingdom, DY1 2HQ
Royal Devon & Exeter NHS Foundation Trust
Exeter, United Kingdom, EX2 5DW
Gateshead Health NHS Foundation Trust
Gateshead, United Kingdom, NE9 6SX
Harrogate and District NHS Foundation Trust
Harrogate, United Kingdom, HG2 7SX
The Leeds Teaching Hospitals NHS Trust
Leeds, United Kingdom, LS1 3EX
University Hospitals of Leicester NHSTrust
Leicester, United Kingdom, LE5 4PW
United Lincolnshire Hospitals NHS Trust
Lincoln, United Kingdom, LN2 5QY
Norwich and Norwich University Hospitals NHS Foundation Trust
Norwich, United Kingdom, NR4 7UY
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom, NG7 2UH
Royal Berkshire NHS Foundation Trust
Reading, United Kingdom, RG1 5BS
Sheffield Teaching Hospitals NHS Foundation Trust
Sheffield, United Kingdom, S5 7AU
City Hospitals Sunderland NHS Foundation Trust
Sunderland, United Kingdom, SR4 7TP
Royal Wolverhampton Hospitals NHS Trust
Wolverhampton, United Kingdom, WV10 0QP
Sponsors and Collaborators
Nottingham University Hospitals NHS Trust
Layout table for investigator information
Principal Investigator: Frances Game, FRCP Derby Hospitals NHS Foundation Trust

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Nottingham University Hospitals NHS Trust Identifier: NCT02224742     History of Changes
Other Study ID Numbers: 12EN005
ISRCTN27665670 ( Other Identifier: ISRCTN )
First Posted: August 25, 2014    Key Record Dates
Last Update Posted: June 25, 2018
Last Verified: June 2018

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases